Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

TriageLogic® Announces Free 30-Day Trial of Their Telephone Triage Software for Telehealth Coordination


News Image

Streamlining the triage process cuts down on unnecessary office or ED visits and assists with coordinating e-visits, in turn saving on healthcare costs.

TriageLogic’s nurse triage software, MyTriageChecklist, has been trusted by doctors and contact centers for nearly a decade to help nurses determine the most appropriate level of care when patients call with symptoms. MyTriageChecklist is a web-based, safe, and efficient solution for organizations looking to increase their quality of patient care and save on healthcare costs. The platform uses Schmitt-Thompson protocols. These protocols are accepted by the wider medical community as the safest protocols to use for doctors to safely delegate care to their nurses.

The software ensures that nurses ask the correct questions and find the right disposition for every call. It works with existing Electronic Medical Records systems (or EMR), and can be securely accessed directly from the internet without additional software or downloads.

For the first time, TriageLogic is giving organizations 30 free days to use the software and experience its benefits which include saving time, ensuring appropriate patient care advice and documentation, and increased patient and nurse satisfaction. The software allows doctors to rest assured that their patients are receiving the most appropriate disposition every time they call. TriageLogic also includes free training by its experienced call center nurse manager, Rose Moon, RN.

What MyTriageChecklist Includes

Once organizations sign up for a free trial, they have instant access to the software. It’s created to be user-friendly, and TriageLogic provides additional resources to make it easy for nurses to learn the software and tips on how to select the right protocols. This includes free live training by our experienced call center manager as well as courses on telephone nurse triage in the free learning center.

On the first page in the software, practices are able to watch a quick training video to help them get started. If more help is needed, then weekly, free live training sessions are available. Every Thursday at Noon our experienced nurse manager Rose Moon gives a live demo, and gives nurses the opportunity to ask questions to better understand the nurse triage process. Support is available through the entirety of the 30 days.

How Does the Software Work?

The patient calls and gives an overview of their symptom and the triage nurse enters symptom “keywords” to quickly access the correct protocol. The nurse uses the Schmitt-Thompson based protocol checklist to ask all the right questions and directs the patient to appropriate level of care or disposition, whether that’s home care, an e-visit, or an urgent care visit. As the nurse handles the call, the telephone triage system documents all the details of the call.

The protocols guide the nurse through the call and makes sure that consistent care is being administered. With clear guidelines to follow and a simple step-by-step process, each patient receives a thorough assessment. These protocols help guard against human error or mistakes, which lessens liability on practices. The Schmitt-Thompson protocols provide coverage for pediatric, adult, and women’s health concerns and they are used by over 90% of nurse call centers around the country. Telephone triage protocols are also a great training tool for new nurses.

The Value

Streamlining the triage process cuts down on unnecessary office or ED visits and assists with coordinating e-visits, in turn saving on healthcare costs. MyTriageChecklist also helps with nurse training and gives new nurses all the tools they need to succeed. In addition to the clear, simple protocols, nurses have access to TriageLogic’s Learning Center which is filled with blogs, videos, and outside references.

The system enables nurses to email or text care advice to the patients for reference after the call, helping to encourage the patient to follow through with their care plan. This is incredibly helpful as the healthcare industry continues to evolve and adapt to remote solutions.

MyTriageChecklist is an easy to use, secure, effective solution that can help your practice adapt to major health events, such as COVID-19. If you are interested in finding out how TriageLogic can help your office, sign up for our 30 day trial or contact us today.

About TriageLogic®

TriageLogic is a URAC-accredited, physician-led provider of top-quality nurse telehealth technology, mobile applications, and medical call center solutions, all with the purpose of encouraging positive patient behavior and improving access to healthcare. Founded in 2006, the TriageLogic Group now serves more than 9,000 physicians and covers over 20 million lives nationwide. They continue to partner with private practices, hospitals, and corporations throughout the U.S.

Share article on social media or email:

SSM Health First in Wisconsin To Select ESO Health Data Exchange To Improve Community Health and Safety


This technology is the future of healthcare, setting the standard for integration between the prehospital and hospital environments.

SSM Health is the first hospital system in Wisconsin to choose ESO Health Data Exchange (HDE). The staff of SSM Health will have access to timely, actionable data on patients arriving by ambulance, creating near real-time insights for more accurate assessments and treatment options. Additionally, EMS agencies will have more clinical information regarding patient outcomes to help improve the overall patient experience.

“This technology is the future of healthcare, setting the standard for integration between the prehospital and hospital environments,” said Dr. Kacey Kronenfeld, SSM Health EMS Program Medical Director. “It will allow us to streamline the way we communicate with our EMS partners, and thus, provide a higher level of exceptional care to our patients. Smooth and efficient information sharing is especially important now as we continue to navigate our way through the COVID-19 pandemic.”

ESO HDE facilitates the bidirectional exchange of data between EMS agencies and hospital emergency departments, ensuring real-time access to important clinical information.

Benefits for SSM Health include:

  • Ensuring continuity in the patient care record for greater efficiency and effectiveness.
  • Increasing timeliness of patient information being shared with emergency departments to improve patient outcomes.
  • Creating a digitally-driven record sharing ecosystem that provides easy access to important clinical information, eliminating the need for unnecessary paperwork.
  • Sharing of data with EMS agencies to close the clinical loop and help improve patient outcomes in the field.

“SSM Health is driving the future of healthcare in its communities,” said Dr. Brent Myers, Chief Medical Officer for ESO. “They are demonstrating the best practice for how emergency departments and EMS agencies can work together to leverage the power of data to create a comprehensive patient picture that will be beneficial for all.”

SSM Health EMS Program leaders are working to expand the ESO HDE to roughly 50 agencies across the south-central Wisconsin region.

About ESO

ESO (ESO Solutions, Inc.) is dedicated to improving community health and safety through the power of data. Since its founding in 2004, the company continues to pioneer innovative, user-friendly software to meet the changing needs of today’s EMS agencies, fire departments, hospitals and state EMS offices. ESO currently serves thousands of customers throughout North America with a broad software portfolio, including the industry-leading ESO Electronic Health Record (EHR), the next generation ePCR; ESO Health Data Exchange (HDE), the first-of-its-kind healthcare interoperability platform; ESO Fire RMS, the gold standard for fire Record Management Systems; trauma, burn and stroke registry software; and ESO State Repository. ESO is headquartered in  Austin, Texas. For more information, visit  http://www.eso.com.

Share article on social media or email:

iOR Partners Welcomes Tom Frinzi to their Board


iOR Partners board member

Tom Frinzi joins the iOR Partners Board of Directors

The ‘setting of care’ is an important part of the overall patient experience and for those practices that make the transition to office-based surgery, I believe they will find it makes not only good medicine but good business.

iOR Partners, the pioneer in office-based surgery (OBS) in ophthalmology announced that industry veteran, Tom Frinzi, has joined their Board of Directors.

“We are thrilled that Tom Frinzi is joining our Board. He brings 40 years of industry expertise and a sterling reputation as a transformative leader,” stated Daniel Durrie, MD., Chairman of the Board of iOR Partners. “Tom’s experience will help us accelerate the next major shift in cataract surgery, the transition to office-based surgery. The integration of clinic and surgery in one location is the way forward to increase surgeons’ flexibility and improve the patient experience while providing the highest level safety. Tom shares our mission of evolving the way ophthalmologic procedures are performed in the U.S. and around the world.”

Frinzi is known for galvanizing organizations with clear goals, building strong operating cultures and high-performance management teams committed to customer, employee and shareholder successes. He recently retired from Johnson & Johnson Vision where he held the position of World Wide President, Surgical. His career includes experience as a C-Suite Executive with a 20+ year reputation of clinical-to-commercial transition and next level growth within small- to mid-size private equity enterprises and Fortune 500 corporations. Frinzi previously served as President of Abbott Medical Optics, President/CEO of WaveTech Vision, Global Commercial Operations at Bausch & Lomb, and CEO of Refractec, Inc.

“I’m excited to be joining the Board of iOR Partners,” said Tom Frinzi. “The ‘setting of care’ is an important part of the overall patient experience and for those practices that make the transition to office-based surgery, I believe they will find it makes not only good medicine but good business.”

To learn more about iOR partners, visit iorpartners.com.

About iOR Partners:

iOR Partners, LLC is paving the way for the future of cataract surgery with innovative, office-based surgery suites that are unique and separate from the traditional, multi-specialty ASC. iOR surgical suites provide cataract surgeons the ability to offer more personalized care in a safe and comfortable surgical environment. Their turnkey solution includes assistance with space build-out, acquiring surgical equipment, staff training, insurance contracting and accreditation and compliance services. iOR Partners is the only company dedicated to ophthalmic office-based surgery suites and has established more than 100 office-based suites nationwide.

Share article on social media or email:

Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline


As a key part of our in vivo medicines and engineered cell medicines manufacturing strategy, we are pleased to partner with Catalent to manufacture and secure our clinical supply.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that they have entered into a strategic partnership whereby Catalent will provide support for the development, manufacturing, and clinical supply of Editas Medicine’s current and future portfolio of in vivo CRISPR medicines and engineered cell medicines.

To date, Catalent has undertaken manufacturing and related services for Editas Medicine at its gene therapy manufacturing facility in Baltimore, Maryland. Through the extended partnership, Catalent will provide further services to include development and manufacturing of Editas Medicine’s complex cell and gene medicines from its best-in-class facilities in Harmans/BWI, Maryland, and Houston, Texas. In addition, Catalent will play an integral part in delivering these vital therapies from its Philadelphia facility to clinical trial sites for administration to patients. Catalent’s integrated support will range from supplying critical raw materials, viral vectors, and engineered cell medicine production to storage and distribution of finished product for clinical trials.

Harry Gill, Editas Medicine’s Senior Vice President of Operations, commented, “As a key part of our in vivo medicines and engineered cell medicines manufacturing strategy, we are pleased to partner with Catalent to manufacture and secure our clinical supply – the latter being a critical component to ensure we can deliver the transformative medicines we are developing to clinical trial sites and patients participating in the study.”

“Catalent is proud to collaborate with Editas in its efforts to bring new targeted and durable CRISPR-based medicines to patients,” said Julien Meissonnier, Catalent’s Chief Scientific Officer. “Together, we have established a unique, integrated model enabling access to Catalent’s advanced cell and gene therapy technologies and clinical supply services. We value early partnerships with innovators and pioneers such as Editas, to enable the emergence of new therapeutic modalities by developing reliable, scalable manufacturing processes, and accelerating access to first-in-human studies.”

Catalent’s cell and gene therapy facilities include the new 32,000 square feet (3,000 square meter) cell therapy clinical facility near Houston, which is expected to be fully validated in 2020, as well as a clinical facility in Gosselies, Belgium, with a dedicated commercial-scale plant currently under construction and expected to be fully commissioned in 2021. The state-of-the-art Harmans/BWI commercial gene therapy manufacturing facility is equipped with single-use technology and includes over 200,000 square feet (19,600 square meters) of late-stage clinical and commercial-stage gene therapy production capabilities. The Harmans/BWI facility is one of Catalent’s five clinical through commercial scale gene therapy facilities in Maryland.

Catalent is a global leader in clinical supply services, with comprehensive and flexible solutions for small molecules, biologics, and cell and gene therapies and integrated solutions to accelerate speed to clinic. The Philadelphia facility has recently expanded its cryogenic handling capabilities to meet the growing demand for clinical supply of cell and gene therapy trials. Catalent has nine GMP clinical packaging facilities and over 50 strategically located depots on six continents for global clinical trial support.

About Catalent Cell & Gene Therapy

Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing to position Catalent as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global network of clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. Catalent Cell & Gene Therapy has produced more than 100 cGMP batches across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com/cell-gene-therapy/.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

About Editas Medicine

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit http://www.editasmedicine.com.

Editas Medicine’s Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

Kensington Recommends the Top 10 Products for Virtual Learning This Fall


News Image

“Our recommended products include ergonomic solutions that improve posture and proper hand positioning while sitting at computers or laptops, and productivity solutions to maximize device connectivity,” Lisa Schuiteboer, a certified ergonomic expert and ergonomic category manager at Kensington

Kensington®, the worldwide leader of desktop computing and mobility solutions for IT, business, and home office professionals and The Professionals’ Choice, announced a recommended Top 10 List of the Best Virtual Learning products that can aid K-12, college and even professionals as they learn and work from home this fall. A survey published earlier this month by The Harris Poll, reported that two-thirds of parents in the U.S. say their kids will learn from home this fall as the COVID-19 pandemic continues.

Not all households have desks and chairs that are suitable for working on a laptop, which means that students are likely sitting at the kitchen table or counter in a chair that is not ideally suited to them. In areas where virtual learning has become the required mode of education this school year, establishing and properly designing a designated workspace in the home is critical to improving productivity, wellness and comfort for students. The use of ergonomic accessories like seat rests, back rests and laptop/monitor stands, enables users to easy adapt existing workspaces to provide a more comfortable and healthier workstation with a relatively small investment.

Kensington recommends the following ten products which can be used to reduce eye strain, improve posture, mitigate neck, hand, arm and back issues, reduce fatigue and optimize the use of computers and/or laptops.

1. Ergonomic Keyboard

2. Mouse and/or Trackball

3. Wrist Rests for Mouse and Keyboard

4. Back Rest

5. Seat Cushion

6. Foot Rest

7. Laptop Riser or Monitor Stand

8. Headphones

9. USB Hub

10. Rugged Case

“Our recommended products include ergonomic solutions that improve posture and proper hand positioning while sitting at computers or laptops, productivity solutions to maximize device connectivity, and even rugged cases to keep tablets protected from occasional falls,” said Lisa Schuiteboer, a certified ergonomic expert and ergonomic category manager at Kensington. “When used correctly, many of these recommended products can help reduce injury such as carpal tunnel, neck strain and other body aches.”

In addition to using products that help improve wellness, there are activities that students can do to help reduce fatigue. Looking away from their screens for 20 seconds every 20 minutes can significantly reduce eye strain, and stretching their hands, wrists and legs at regular intervals can reduce strain and extend productivity over long periods at the computer. The Kensington Stretch Guide provides some great recommendations for easy, quick exercises to do throughout the day.

Kensington recently hosted a webinar on utilizing the proper ergonomic principles to increase comfortability and productivity while learning from home. The webinar, titled “Ergo 101 – How Ergonomics Can Help Students with eLearning,” can be viewed here.

All ten recommended virtual learning products are immediately available and can be found on the Kensington website or at online retailers such as Amazon.

Follow Kensington on:

About Kensington

Kensington is a leading provider of desktop and mobile device accessories, trusted by IT, educators, business, and home office professionals around the world for more than 35 years. Kensington strives to anticipate the needs and challenges of the ever-evolving workplace and craft professional-tier award-winning solutions for organizations committed to providing peak professionals the tools they need to thrive. The company prides itself as The Professionals’ Choice, and on its core values surrounding design, quality, and support.

In office and mobile environments, Kensington’s extensive portfolio of award-winning products provides trusted security, desktop productivity innovations, and ergonomic well-being.

Headquartered in San Mateo, California, Kensington is the inventor and worldwide leader in laptop security locks. Kensington is a division of ACCO Brands (NYSE: ACCO), one of the world’s largest designers, marketers, and manufacturers of branded business, academic, and consumer products, sold in more than 100 countries across the globe.

Kensington is a registered trademark of ACCO Brands. Kensington The Professionals’ Choice is a trademark of ACCO Brands. All other registered and unregistered trademarks are the property of their respective owners.

© 2020 Kensington Computer Products Group, a division of ACCO Brands. All rights reserved.

Contact:

Ken Hagihara

Integrity PR

949-768-4423 x101

ken@integritypr.net

Share article on social media or email:

BioFactura Awarded $1 Million SBIR Contract for Development of a Marburg Virus Therapeutic


News Image

“We look forward to working with our partners at the DoD to develop the drug manufacturing process for advanced testing and clinical readiness to meet threats to the warfighter.” – Dr. Darryl Sampey, President and CEO, BioFactura

BioFactura, Inc. today announced a $1 million Small Business Innovation Research (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of Defense (DoD). The goal of this project is to develop, optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement needs for rapid manufacture of a monoclonal antibody (mAb) therapeutic against the Marburg virus (MARV) biothreat.

MARV is a member of the same family as Ebola virus, causes lethal viral hemorrhagic fever, and is classified as a Category A priority pathogen by the NIH, due to high case fatality rates and suspected weaponization. There are currently no MARV vaccines or therapeutics approved for human use. With so much focus on Ebolavirus over the last few years, MARV antibody development efforts have lagged considerably and few MARV-specific mAbs have been described. This problem leaves the U.S. in a vulnerable situation to treat and manage a MARV outbreak. Under the contract, BioFactura will use its proprietary StableFastTM Biomanufacturing Platform to develop a process for this crucial therapy against MARV that is easily scalable for production at large manufacturing cGMP (current Good Manufacturing Practices) facilities.

Dr. Darryl Sampey, President and CEO of BioFactura, stated, “This Chem-Bio Defense Phase II award builds upon our successful early development of a highly productive StableFast cell line during the SBIR Phase I contract. We look forward to working with our partners at the DoD to develop the drug manufacturing process for advanced testing and clinical readiness to meet threats to the warfighter.”

“This government contract for the development of a novel Marburg virus therapeutic countermeasure is the

result of continued efforts to create highly effective therapeutics that can be deployed in the event of a biological threat. The current COVID pandemic has taught us a valuable lesson: Strategic preparedness in conjunction with an organized effort at containment and treatment, can mitigate the effects of these deadly pathogens. We applaud the JSTO-CBD and DoD for their foresight,” said Jeffrey Hausfeld MD. MBA., Chairman and Chief Medical Officer of BioFactura, Inc.

This project is supported by the Defense Threat Reduction Agency under Contract No. HDTRA1-20-C-0033. Any opinions, findings and conclusions or recommendations expressed in this press release are those of the

authors and do not necessarily reflect the views of Defense Threat Reduction Agency.

About BioFactura, Inc.

BioFactura, Inc. (Frederick MD) develops and commercializes high-value biodefense medical countermeasures and biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 15 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases. http://www.biofactura.com

Share article on social media or email:

Murrieta Genomics Named “The Most Influential HealthTech Company to Watch in Genomic Solutions”


The Healthcare Insights July 2020 Edition

Our management team and advisory board is dedicated to launching the next great genomic companies.

Murrieta Genomics was recently named as a “company to watch” by The Healthcare Insights, a medical publication that discusses developments in medical technology and treatment for better global health in its July 2020 issue.

Murrieta Genomics was selected as “The Most Influential HealthTech Company to Watch in Genomics Solutions” vertical due to the valuable contributions the company is making in this niche. For a digital copy of the story, click here.

“It is a great honor to be selected by The Healthcare Insights team,” stated Jay Goth, CEO of Murrieta Genomics. “We are a young company but making strides in impacting the genomic space by offering startups in this industry the sequencing and sector knowledge they need to develop their proof of concept. Our management team and advisory board is dedicated to launching the next great genomic companies.”

The print magazine reaches out to over 72,000 subscribers across the United States and Canada. The magazine’s mission is to help readers identify the companies that are bringing reliable and innovative solutions to the healthcare sector.

The July issue features the “20 Most Advanced Healthcare Tech Companies to Watch in 2020” that have pushed the envelope of the healthcare industry with their inspiring ideas and advanced health care solutions.

The magazine contains thought-leadership articles and insights of healthcare experts, doctors, directors of research and development about the advancements in the healthcare sector over the past few years. Subscribers include CIOs, CTOs, Chief Scientific Officers, VPs for Manufacturing/Clinical Research/Clinical Trials/Drug Discovery, Head of Clinical Research, and other technology buyers and leaders.

About Murrieta Genomics

Murrieta Genomics provides access to next generation sequencing technology for researchers in the health, veterinary, agriculture, forensics and direct to consumer industries. The company is a true business incubator, offering mentorship and guidance from both the scientific and business perspective to aspiring genomic-related entrepreneurs. The founders of Murrieta Genomics have extensive background in business, finance, science and technology. They are supplemented with a prestigious advisory board from both business and science. The company provides Next Generation Sequencing (NGS) services, hands-on consulting, review, appraisal and guidance. In addition, it provides help with company value propositions and potential seed funding support to qualified incubator graduates. For more information visit http://www.murrietagenomics.com.

Murrieta Genomics is part of the Murrieta Innovation Center, a RESI Tech Hub dedicated to supporting life science companies. The Innovation Center has medical device, therapeutic, software, clinical research and of course genomic companies that are working hard to advance new ideas and innovations that can impact the world in a positive way. The Center is also a resource for all types of local startup companies, offering services and workshops from a local SBDC, several veteran organizations, a SCORE branch and more.

Share article on social media or email:

Sanare Bioscience, a New Pharmaceutical R&D Firm, Aims to Improve Patient Outcomes with Innovative Approaches


News Image

Our vision at Sanare Bioscience is to impact the world one pharmaceutical study at a time with a goal of innovating and improving patient outcomes.

Jack Donaldson IV, M.Ed., former president of Healthcare Consultant Group, is pleased to announce the organization of a new pharmaceutical research and development company: Sanare Bioscience.

This new entrant into the medical R&D field was organized with a single purpose in mind: to improve patient outcomes through innovative drug development and bridge the most pressing gaps in the drug development industry. These include the following:


  • • Silos within the drug development process
  • • Breakdowns in the supply chain
  • • Lack of reliable funding
  • • Lack of diversity in patient and physician participation
  • • Lack of outreach needed for successful trials


Sanare Bioscience consists of a team of highly qualified innovators, clinicians, scientists, researchers and legal experts with decades of experience analyzing products and protocols. Each team member has fostered significant relationships within the pharmaceutical industry, established unparalleled institutional knowledge and has unique expertise in commercialization.

“Our vision at Sanare Bioscience is to impact the world one pharmaceutical study at a time with a goal of innovating and improving patient outcomes,” said Donaldson, who will serve as CEO of Sanare Bioscience. “This team possesses the talents, relationships and drive needed to make anything significant happen in the expansive healthcare world today. I’m extremely excited to be a part of it.”

The team’s qualifications will allow Sanare the ability to do the following for their partners:

  • • Oversee and support drug clinical trial services and site management
  • • Improve efficiency by streamlining the drug development process.
  • • Eliminate breakdowns in communication in the supply chain from innovator to researcher to clinical trial and finally to drug distributors
  • • Provide professional guidance on solutions that reduce the cost of human capital
  • • Conduct market analysis and drug development partnerships
  • • Cut out unnecessary costs and superfluous protocols


“The Sanare team has a proven track record of both the development drugs that improve patient outcomes and in successfully bringing those drugs to domestic and international markets,” said Dr. Valerie Armstead, chief research officer of Sanare Bioscience. “The ultimate goal of pharmaceutical development is to not only bridge the gaps in the process but to eventually bring new compounds with proven therapeutic effects to the market.”

Sanare Bioscience is also currently partnering with many manufacturers to help supply vital PPE – including face masks, isolation gowns and hand sanitizer – while in the midst of the COVID-19 pandemic.

To learn more about Sanare Bioscience, please visit sanarebioscience.com.

About Sanare Bioscience

Sanare Bioscience is committed to improving patient outcomes by researching and developing innovative medical solutions. With a team of clinicians, scientists, researchers and pharmaceutical legal experts, each with more than 10 years of healthcare and clinical trial experience, Sanare Bioscience is able to research, conduct clinical trials and ultimately bring drugs to the healthcare marketplace. For more information, visit http://www.sanarebioscience.com.

Share article on social media or email:

Elizabeth Justen, Steven Harvey Appointed to the South Broward Hospital District Board of Commissioners


Commissioners Justen and Harvey

“I look forward to helping Memorial Healthcare System and the community,” Justen said. “It is my honor and privilege to serve on the South Broward Hospital District Board of Commissioners,” Harvey added.

Elizabeth Justen and Steven Harvey were appointed this month by Florida Governor Ron DeSantis to the Board of Commissioners of the South Broward Hospital District, which oversees all actions of the Memorial Healthcare System. Justen and Harvey are serving alongside Chairman Douglas A. Harrison, Vice Chair Dr. Luis E. Orta, and Commissioners Jose Basulto, Brad Friedman and Laura Raybin Miller. Justen is also serving as secretary/treasurer on the board. Both of these appointments are for a four-year term.

Justen, a Hollywood resident, is the assistant executive director of the Sheriff’s Foundation of Broward County, a nonprofit organization which funds community programs and initiatives. She is also the key account manager at OFB Marketing and a principal at The Marketing Experience.

“Thank you to the Memorial Healthcare System for the warm welcome. I am honored to be appointed by Governor DeSantis to serve alongside my fellow Commissioners. It is my privilege to be associated with this excellent South Florida landmark,” Justen said. “I look forward to helping Memorial Healthcare System and the community.”

Harvey, of Cooper City, is the assistant dean of operations and administration at Nova Southeastern University, where he previously earned his bachelor’s and master’s degrees in business administration.

“It is my honor and privilege to serve on the South Broward Hospital District Board of Commissioners,” Harvey said. “As a resident of the district for nearly 50 years and a diabetic, I look forward to giving back to a healthcare system that has provided high-quality care to me and my loved ones.”

Memorial Healthcare System is one of the largest public healthcare systems in the U.S. and a national leader in quality care and patient satisfaction. It is highly regarded for a patient and family-centered approach at facilities that include Memorial Regional Hospital, Joe DiMaggio Children’s Hospital, Memorial Regional Hospital South, Memorial Hospital West, Memorial Hospital Miramar, Memorial Hospital Pembroke, Joe DiMaggio Children’s Health Specialty Center in Wellington, and Memorial Manor nursing home.

Among the many awards it has earned are Modern Healthcare magazine’s “Best Place to Work in Healthcare,” Florida Trend’s “Florida’s Best Companies to Work For,” and Becker’s Hospital Review’s “150 Great Places to Work in Healthcare.” In a recent report, “Humanizing Brand Experience,” the Denver-based consulting firm Monigle named Memorial the top health system brand in America, based on consumer surveys. To learn more, visit http://www.mhs.net.

Share article on social media or email:

Anomet Medical Introduces Clad Wire That Can Combine up to Three Different Materials for use in Implantable Devices


News Image

Anomet Medical Clad Wire can combine up to three materials to meet specific design requirements, performance, and cost criteria.

This wire is ideal for meeting design criteria for corrosion resistance, wear resistance, contact resistance, biocompatibility, radiopacity, strength, conductivity, solderability, formability and more.

Anomet Products has introduced new custom composite medical clad wire that can combine up to three different materials for use with CRM, neurostimulation, vascular, and related devices.

Anomet Medical Clad Wire can combine up to three materials to meet specific design requirements, performance, and cost criteria; especially where solid wire is limited. Typical configurations for implantable devices include: Platinum-iridium clad tantalum, Platinum clad MP35N®, Silver cored MP35N®, 316LVM clad tantalum, Nitinol clad platinum, and Gold clad nitinol.

Ideally suited for meeting design criteria for corrosion resistance, wear resistance, contact resistance, biocompatibility, radiopacity, strength, conductivity, solderability, formability and more, Anomet Medical Clad Wire has a smooth consistent finish and can be manufactured in sizes from 0.002” to 0.125” O.D. with 2% or more cladding thickness.

Anomet Medical Clad Wire is priced according to configuration and quantity. Samples and price quotations are available upon request.

For more information contact:

Anomet Products, Inc.

Daniel F. Lambert, Technical Marketing

830 Boston Turnpike

Shrewsbury, MA 01545

(857) 302-2523 FAX (508) 842-0847

e-mail: dlambert@anometproducts.com

http://www.anometproducts.com

Share article on social media or email: